Total Raised

$38.83M

Investors Count

17

Deal Terms

2

Funding, Valuation & Revenue

16 Fundings

InSphero has raised $38.83M over 16 rounds.

InSphero's latest funding round was a Grant - VI for on November 18, 2024.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/18/2024

Grant - VI

$XXM

0

FY undefined

2

8/19/2024

Grant - V

$XXM

0

FY undefined

3

3/31/2023

Unattributed VC

ZEISS Ventures, and Undisclosed Investors

$XXM

0

FY undefined

2

1/20/2023

Grant - IV

$XXM

$XXM

0

FY undefined

10

9/17/2019

Incubator/Accelerator

$XXM

0

FY undefined

10

Date

11/18/2024

8/19/2024

3/31/2023

1/20/2023

9/17/2019

Round

Grant - VI

Grant - V

Unattributed VC

Grant - IV

Incubator/Accelerator

Amount

$XXM

Investors

ZEISS Ventures, and Undisclosed Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

3

2

10

10

Start free trial
New call-to-action

InSphero Deal Terms

2 Deal Terms

InSphero's deal structure is available for 2 funding rounds, including their Series B from June 18, 2013.

Round

Series B

Series A

Funding Date

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$XXM

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

Board Voting

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

InSphero Investors

17 Investors

InSphero has 17 investors. European Union invested in InSphero's Grant - VI funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/18/2024

11/18/2024

1
Grant - VI

Government

Belgium

8/19/2024

8/19/2024

1
Grant - V

Non-Profit Foundation

New York

3/31/2023

3/31/2023

1
Unattributed VC

Corporate Venture

Germany

00/00/0000

00/00/0000

European Commission

Subscribe to see more

Government

Belgium

00/00/0000

00/00/0000

Euronext

Subscribe to see more

Corporation

Netherlands

First funding

11/18/2024

8/19/2024

3/31/2023

00/00/0000

00/00/0000

Last Funding

11/18/2024

8/19/2024

3/31/2023

00/00/0000

00/00/0000

Investor

European Commission

Euronext

Rounds

1
Grant - VI
1
Grant - V
1
Unattributed VC

Subscribe to see more

Subscribe to see more

Board Seats

Type

Government

Non-Profit Foundation

Corporate Venture

Government

Corporation

Location

Belgium

New York

Germany

Belgium

Netherlands

InSphero Acquisitions

1 Acquisition

InSphero acquired 1 company. Their latest acquisition was Doppl on November 11, 2025.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/11/2025

Debt

$XXM

$0.68M

Acquired

4

Date

11/11/2025

Investment Stage

Debt

Companies

Valuation

$XXM

Total Funding

$0.68M

Note

Acquired

Sources

4

New call-to-action

Compare InSphero to Competitors

Emulate Logo
Emulate

Emulate specializes in advanced in vitro models for research and development in the biotechnology sector. The company offers a human emulation system that includes instruments, consumables, and software designed to mimic human biology and predict human responses to various stimuli. Emulate's technology is primarily utilized in the fields of drug development and disease research. It was founded in 2014 and is based in Boston, Massachusetts.

Stemnovate Logo
Stemnovate

Stemnovate focuses on drug discovery in the pharmaceutical industry. It has a drug discovery platform that uses multi-organ modelling to evaluate the metabolism and toxicity of drug molecules, to improve clinical trials and patient safety. Stemnovate also offers services including biobanking, cellular reprogramming, and computational modelling to aid in drug development and precision medicine. It was founded in 2016 and is based in Cambridge, United Kingdom.

T
TissUse

TissUse is a biotechnology company that develops a 'Multi-Organ-Chip' technology platform for preclinical testing in the pharmaceutical sector. The company provides products that simulate the activity of multiple human organs for research and development purposes, to predict drug toxicity, absorption, distribution, metabolism, and excretion (ADME) profiles, and efficacy in vitro. TissUse serves sectors involved in drug development, cosmetics, food and nutrition, and consumer products. It was founded in 2010 and is based in Berlin, Germany.

MIMETAS Logo
MIMETAS

MIMETAS focuses on human tissue models for drug discovery within the biotechnology sector. The company provides a platform for creating organ-on-a-chip models that replicate human tissues and disease biology to aid in drug efficacy and safety testing. MIMETAS primarily serves the pharmaceutical industry, supporting research and development in therapeutic areas including oncology, immunology, and neurology. It was founded in 2013 and is based in Leiden, Netherlands.

28bio Logo
28bio

28bio specializes in neurotechnology engineering human brain models for the neuroscience sector. The company provides a platform that combines tissue engineering, neural interfacing, and artificial intelligence to develop models with functions like memory, learning, and cognition. It serves the biopharmaceutical industry, offering tools for drug discovery and development. 28bio was formerly known as AxoSim Technologies. It was founded in 2014 and is based in New Orleans, Louisiana.

React4life Logo
React4life

React4Life is a biotech company involved in preclinical research technologies within the biotech and pharmaceutical sectors. They provide MIVO technology, an organ-on-chip system that simulates human biology for drug testing and personalized medicine. The company's services involve laboratory integration of their technology and the development of specific assays for research. It was founded in 2016 and is based in Genova, Italy.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.